Literature DB >> 19371479

What is the pathologist saying? Interpretation of the prostate pathology report.

Omar Hameed1.   

Abstract

Management of patients presenting with elevated serum prostate-specific antigen levels, or those with previously diagnosed prostate carcinoma, is very much dependent on the pathology report on needle biopsy or radical prostatectomy specimens obtained from these patients. In contrast to a diagnosis of benignity or high-grade prostatic intraepithelial neoplasia, a diagnosis of atypia on needle core biopsy is usually an indication for a repeat biopsy; however, it is important to understand that atypia and other related terms are not specific diagnoses. The pathology report on different prostate specimens with a diagnosis of carcinoma usually includes the Gleason grade and extent of carcinoma among other morphological prognostic and predictive factors. Understanding the significance of these morphological factors and how they are evaluated and incorporated into the pathology report, as well as newer developments in this field, can assist urologists in the interpretation of the pathological findings and ultimately lead to better clinical care.

Entities:  

Mesh:

Year:  2009        PMID: 19371479     DOI: 10.1007/s11934-009-0036-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  39 in total

1.  The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system.

Authors:  C C Pan; S R Potter; A W Partin; J I Epstein
Journal:  Am J Surg Pathol       Date:  2000-04       Impact factor: 6.394

2.  The proportion of cores with high-grade prostatic intraepithelial neoplasia on extended-pattern needle biopsy is significantly associated with prostate cancer on site-directed repeat biopsy.

Authors:  Ardavan Akhavan; Jonathan D Keith; Sheldon I Bastacky; Chao Cai; Yun Wang; Joel B Nelson
Journal:  BJU Int       Date:  2007-04       Impact factor: 5.588

3.  The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.

Authors:  Liang Cheng; Michael O Koch; Beth E Juliar; Joanne K Daggy; Richard S Foster; Richard Bihrle; Thomas A Gardner
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

4.  Granulomatous prostatitis on needle biopsy.

Authors:  J R Oppenheimer; H Kahane; J I Epstein
Journal:  Arch Pathol Lab Med       Date:  1997-07       Impact factor: 5.534

5.  Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues.

Authors:  P A Humphrey; R T Vollmer
Journal:  Mod Pathol       Date:  1997-04       Impact factor: 7.842

6.  Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications.

Authors:  E T Ruijter; C A van de Kaa; J A Schalken; F M Debruyne; D J Ruiter
Journal:  J Pathol       Date:  1996-11       Impact factor: 7.996

7.  Cancer volume of lymph node metastasis predicts progression in prostate cancer.

Authors:  L Cheng; E J Bergstralh; J C Cheville; J Slezak; F A Corica; H Zincke; M L Blute; D G Bostwick
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

Review 8.  Immunohistochemistry in diagnostic surgical pathology of the prostate.

Authors:  Omar Hameed; Peter A Humphrey
Journal:  Semin Diagn Pathol       Date:  2005-02       Impact factor: 3.464

9.  Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Authors:  Christos N Papandreou; Danai D Daliani; Peter F Thall; Shi-Ming Tu; Xuemei Wang; Adriana Reyes; Patricia Troncoso; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

10.  Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.

Authors:  Joost L Boormans; Mark F Wildhagen; Chris H Bangma; Paul C Verhagen; Geert J van Leenders
Journal:  BJU Int       Date:  2008-08-14       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.